- Use of drugs that, in the opinion of the investigator, have a strong potential for renal or hepatic toxicity within 2 weeks before the start of anetumab ravtansine until the EoT visit.Use of drugs with known renal or hepatic toxicity within 2 weeks before the start of anetumab ravtansine until the EoT (end of treatment) visit